Metabolic dysfunction-associated steatohepatitis (MASH, previously referred to as non-alcoholic steatohepatitis or NASH) is a disease characterized by excess fat accumulation, inflammation, and fibrosis of the liver, leading to increased morbidity and mortality. Despite increasing prevalence globally, MASH has remained underrecognized, underdiagnosed, and undertreated.
However, shifting guidelines and nomenclature, and the recent FDA approval of the first ever MASH-targeted therapy, has set up 2024 to be a catalyst year in the fight against MASH. In this brief, we lay out additional challenges to clear for MASH development to take off in 2024 and beyond. We also lay out some considerations for manufacturers to help “futureproof” their development programs in this complex and competitive treatment landscape.
